Shota Rustaveli National Science Foundation of Georgia disseminates information about the 14^th grant call of Innovative Medicines Initiative (IMI).

The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalized medicines for the health and wellbeing of all, especially in areas of unmet medical need.

Call includes issues of medical field, and focuses on next main topics:

Topic 1: Targeted immune intervention for the management of non-response and relapse;

Topic 2: Non-invasive clinical molecular imaging of immune cells;

Topic 3: Development of a platform for federated and privacy-preserving machine learning in support of drug discovery;

Topic 4: Centre of excellence – remote decentralised clinical trials;

 

The goal of IMI, particularly in its second phase (IMI2, 2014-2020) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. Our projects will provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments.

Particularly programme aims to improve overall drug development process, develop diagnostic and treatment biomarkers for diseases clearly linked to clinical relevance and approved by regulators, reduce the period to reach clinical proof of concept in medicine development, such as for cancer and immunological diseases.

• Short proposals must be submitted via the electronic submission system of the Horizon 2020 Participant Portal.
• Deadline for submitting the projects: June 14, 2018 20:00 GMT (1 stage);
• Deadline for submitting the projects: December 11, 2018 (2 stage).
• For additional information about IMI2 please visit the web-site.

Please, find the detailed information  and necessary documentation for the call.